RESTASIS

Font Size : Normal | Large

Not a health care professional?
Please visit our site for patients

Potential Long-Term Impact of Chronic Dry Eye

If left untreated, Chronic Dry Eye1

  • Can potentially damage tissues of the eye’s surface
  • Can result in permanent damage to the cornea and impair vision
  • Can also increase vulnerability to other eye infections

 

 

References

  1. Albietz JM. Dry eye: an update on clinical diagnosis, management and promising new treatments. Clin Exp Optom. 2001:84:4-18.
Email this page
Allergan, Inc.

© 2007 Allergan, Inc. All rights reserved | Privacy Statement | FAQs | Terms of Use | Site Map
This information is intended for residents of the United States. ® and ™ marks owned by Allergan, Inc.

RESTASIS® Ophthalmic Emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Important Safety Information:

RESTASIS® is contraindicated in patients with active ocular infections and has not been studied in patients with a history of herpes keratitis.

The most common adverse event was ocular burning (upon instillation) – 17%. Other events reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).

Please see full prescribing information for RESTASIS® (cyclosporine ophthalmic emulsion) 0.05%.